SK bioscience reported a first-quarter net loss attributable to shareholders of 33.3 billion won, widening sharply from a 7.5 billion won loss a year earlier. Operating loss also widened to 44.5 billion won from 15.1 billion won, indicating deteriorating profitability in the period.
SK bioscience reported a first-quarter net loss attributable to shareholders of 33.3 billion won, widening sharply from a 7.5 billion won loss a year earlier. Operating loss also widened to 44.5 billion won from 15.1 billion won, indicating deteriorating profitability in the period.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly negative
Sentiment Score
-0.55
